These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 27104935)

  • 1. Authors' response: Meningococcal vaccine antigen diversity in global databases.
    Brehony C; Hill DM; Lucidarme J; Borrow R; Maiden MC
    Euro Surveill; 2016 Apr; 21(15):. PubMed ID: 27104935
    [No Abstract]   [Full Text] [Related]  

  • 2. Prospects for eradication of meningococcal disease.
    Nadel S
    Arch Dis Child; 2012 Nov; 97(11):993-8. PubMed ID: 22984187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neisseria meningitidis serogroup B vaccine development.
    Caesar NM; Myers KA; Fan X
    Microb Pathog; 2013 Apr; 57():33-40. PubMed ID: 23416222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Meningococcal serogroup B vaccines].
    Dommergues MA
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S65-9. PubMed ID: 22883369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quadrivalent meningococcal conjugate vaccines.
    Pace D; Pollard AJ; Messonier NE
    Vaccine; 2009 Jun; 27 Suppl 2():B30-41. PubMed ID: 19477560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B Disease.
    Zlotnick GW; Jones TR; Liberator P; Hao L; Harris S; McNeil LK; Zhu D; Perez J; Eiden J; Jansen KU; Anderson AS
    Hum Vaccin Immunother; 2015; 11(1):5-13. PubMed ID: 25483509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meningococcal vaccine antigen diversity in global databases.
    Brehony C; Hill DM; Lucidarme J; Borrow R; Maiden MC
    Euro Surveill; 2015; 20(49):. PubMed ID: 26676305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Meningococcal vaccines: from polysaccharide to conjugate vaccines].
    Cohen R; Levy C
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of group B meningococcal disease by vaccination: a difficult task.
    Thomas M
    N Z Med J; 2004 Aug; 117(1200):U1016. PubMed ID: 15475986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serogroup B Meningococcal Disease Vaccine Recommendations at a University, New Jersey, USA, 2016.
    Soeters HM; Dinitz-Sklar J; Kulkarni PA; MacNeil JR; McNamara LA; Zaremski E; Chang HY; Lujan E; Granoff D; Lasky M; Montana B
    Emerg Infect Dis; 2017 May; 23(5):867-869. PubMed ID: 28418307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines.
    Sanders H; Feavers IM
    Expert Rev Vaccines; 2011 Mar; 10(3):323-34. PubMed ID: 21434800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of Bexsero® Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: Implications for immunisation.
    Brehony C; Rodrigues CMC; Borrow R; Smith A; Cunney R; Moxon ER; Maiden MCJ
    Vaccine; 2016 Sep; 34(39):4690-4697. PubMed ID: 27521232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serogroup B meningococcal vaccines-an unfinished story.
    Sadarangani M; Pollard AJ
    Lancet Infect Dis; 2010 Feb; 10(2):112-24. PubMed ID: 20113980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges and progress in the development of a serogroup B meningococcal vaccine.
    Lewis S; Sadarangani M; Hoe JC; Pollard AJ
    Expert Rev Vaccines; 2009 Jun; 8(6):729-45. PubMed ID: 19485754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The challenge of post-implementation surveillance for novel meningococcal vaccines.
    Snape MD; Medini D; Halperin SA; DeTora L; Drori J; Moxon ER
    Vaccine; 2012 May; 30 Suppl 2():B67-72. PubMed ID: 22230578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
    Pace D
    Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
    Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
    Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meningococcal serogroup B infections: a search for a broadly protective vaccine.
    Vermont CL; van den Dobbelsteen GP
    Expert Rev Vaccines; 2003 Oct; 2(5):673-81. PubMed ID: 14711328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent developments in vaccines to prevent meningococcal serogroup B infections.
    Vermont CL; van den Dobbelsteen GP; de Groot R
    Curr Opin Mol Ther; 2003 Feb; 5(1):33-8. PubMed ID: 12669468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of serogroup B meningococcal disease.
    Stephens DS
    Lancet; 2012 Feb; 379(9816):592-4. PubMed ID: 22260987
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.